Why retatrutide discussion here is more cautious than elsewhere

Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below.

A question about retatrutide discussion that I think has a definite answer, unlike most of what I ask here.

I have the reasoning below and I am fairly confident about the direction. I am not confident about the size, and the size is what the decision turns on.

Retatrutide is investigational. Material obtained outside a clinical trial is research-use-only by definition, is not approved for human use, and carries no assurance about its identity or content beyond whatever independent testing you commission yourself.

Answering the question the opening post raises rather than the one it answers.

Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not assume a theoretical mass. The theoretical mass is not published in peer-reviewed literature for retatrutide at present.

That is the version I use. It may not be the version that is correct.

On retatrutide discussion I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.

Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.

Everything in post #5 holds. The case it does not cover is the one I have.

A theoretical mass for retatrutide is not published in the peer-reviewed literature in a form worth quoting. A report should state the mass observed on the instrument rather than assert agreement with a figure nobody can check.

That has held every time I have looked, which is not the same as always.

That is a cleaner way of putting what I was circling around.

Post #5 and I disagree about the size of the effect, not about the direction.

Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.

I looked this up rather than remembered it, which is the right order.

Taking post #9 at face value and following it one step further.

I have no financial interest in anything named in this thread and I want to say so before I comment on retatrutide discussion, because it is the sort of subject where it matters.

Taking post #10 at face value and following it one step further.

Why this subcategory is more cautious than elsewhere: retatrutide is investigational, phase 3 is ongoing, and the heart-rate signal in phase 2 is not negligible. Caution is proportionate to the evidence status.

Post #9 and I disagree about the size of the effect, not about the direction.

No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.

What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.

Marking that as an opinion rather than a finding.